Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to...
33 insider purchases on record · latest filing 2026-03-05.
Insiders have also filed 153 sale transactions at AKBA.